Celebrating Excellence in Cell and Gene Therapy
OXB, a distinguished contract development and manufacturing organization (CDMO), has been awarded in the 'Cell & Gene Therapy – Global' category at the latest CDMO Leadership Awards. This recognition highlights OXB's commitment to quality and innovation within the burgeoning field of cell and gene therapy, showcasing its robust capabilities across a comprehensive global network.
About OXB's Achievement
The CDMO Leadership Awards serve as a benchmark for industry excellence, derived from independent surveys of biopharma and biotechnology stakeholders. Leaders within these fields assess CDMOs based on critical performance metrics, focusing on quality, service, and innovation. OXB's accolade underscores its prowess in providing top-tier manufacturing services and confirms its standing as a leader in the cell and gene therapy sector.
Insights from Leadership
Dr. Sebastien Ribault, the Chief Business Officer of OXB, expressed his pride in the honor. He stated, "This award signifies our hard work and strategic vision as a specialized CDMO in the realm of cell and gene therapies. Our legacy of over three decades in viral vector innovation, coupled with our commitment to collaborative partnerships, reinforces our goal to deliver transformative therapies to patients globally." This sentiment echoes across the entire OXB team, emphasizing a shared commitment to quality and impactful outcomes in therapy development.
Commercial Growth and Demand
As OXB was recognized, the company is experiencing a surge in demand for its services, particularly across various viral vector types. These vectors are integral to the development of cutting-edge therapies, driving OXB's expansion. Their global client base ranges across multiple stages of development, highlighting OXB's versatility and commitment to aiding partners through the entire lifecycle, from early clinical assessments to commercialization.
OXB's Commitment to Innovation
With a rich history as one of the pioneers in cell and gene therapy, OXB boasts over 30 years of experience specializing in viral vectors. The company's capabilities span from initial vector development to large-scale commercialization, supported by advanced quality assurance systems and regulatory expertise. Their innovative work with lentivirus, adeno-associated virus (AAV), and adenovirus showcases their diverse therapeutic contributions, ensuring that they remain at the forefront of this evolving sector.
Technological Advancements
At the core of OXB's success are unique technologies that enhance their viral vector manufacturing capabilities. Utilizing solutions such as the 4th generation lentiviral vector system, termed the TetraVecta™ system, alongside enhancements in AAV production through a dual plasmid system, OXB continues to set industry standards. Their process development employs both suspension and perfusion methodologies with the implementation of process enhancers, all aimed at streamlining production while maintaining high quality.
Company Overview
Headquartered in Oxford, UK, OXB operates bioprocessing and manufacturing facilities in various locations, including the UK and the US. The company is a proud member of the FTSE4Good Index, illustrating its dedication to sustainable practices and corporate responsibility. OXB collaborates closely with leading pharmaceutical and biotechnology companies, fostering innovation to enhance the delivery of lifesaving therapies worldwide.
Frequently Asked Questions
What is the significance of the CDMO Leadership Awards?
The CDMO Leadership Awards recognize excellence in contract development and manufacturing, with a focus on quality, innovation, and service as evaluated by industry leaders.
How does OXB stand out in the industry?
OXB distinguishes itself through its extensive experience, technological innovations, and a commitment to quality service, making it a leader in cell and gene therapy.
What technologies does OXB utilize for viral vector manufacturing?
OXB employs advanced technologies, including the TetraVecta™ system and dual plasmid systems, to enhance viral vector production while ensuring high standards of quality.
Who can OXB's services benefit?
OXB's services are beneficial for a wide range of clients in the pharmaceutical and biotechnology sectors, from those in early clinical developments to those looking to commercialize their therapies.
How long has OXB been in operation?
OXB has over 30 years of experience in the field of cell and gene therapy, positioning it as a knowledgeable leader in viral vector development and production.
